This is a watershed moment. Moving marijuana to Schedule III ends the long-standing contradiction that it has “no accepted medical use” and formally brings cannabinoids into the health care conversation. It unlocks research, reduces stigma, and most importantly signals to providers and payers that this is a legitimate clinical category that needs to be approached with rigor, not avoided.
This is good news because it removes major barriers to clinical research, enables more structured prescribing pathways and creates real momentum for integrating cannabinoids into evidence-based care. But the bigger win is what it enables: health systems and payers can now start evaluating cannabinoids as true care interventions, particularly for high-burden areas like pain, sleep, anxiety and oncology supportive care. This can become another tool in the toolbox where better symptom control can reduce utilization and improve quality of life.
There are, however, significant concerns. Rescheduling increases access faster than it increases guidance. Millions of Americans are already using cannabis for symptom management, often without clinically sound direction. At the same time, most clinicians don’t feel equipped to guide patients on dosing, product selection or drug interactions. That gap is where risk lives. If we don’t scale clinically responsible use guidance — personalized, evidence-informed and accessible to all patients — we risk repeating the mistakes we’ve seen in other areas of medicine as well as the current fits and starts with cannabis where use outpaced both research and legislation, resulting in inconsistent use, avoidable adverse events, and missed opportunities to reduce reliance on higher-risk medications. Rescheduling creates the opportunity, but it also creates an obligation to build the clinical infrastructure through education, protocols and digital tools that make use safe and effective at scale.
Regarding the administration’s effort to expedite full rulemaking — it’s the right move. The prior pace of rulemaking was out of step with how quickly patient use and state-level markets have evolved, thus leaving us in a more dangerous place where real-world use far outstripped our ability to study and research those impacts. Accelerating the transition to Schedule III brings federal policy closer to clinical reality. But speed should be paired with structure — we need parallel investment in standards of care, research frameworks and clinician enablement so that access expands responsibly, not just rapidly.
The headline is rescheduling, but the real story is what comes next. Cannabinoids are most immediately impactful in supportive care where symptom burden drives cost, suffering and polypharmacy. That’s where we can see near-term clinical and economic value. And importantly, marijuana is only part of the picture. For many health care use cases, barriers exist through state-regulated marijuana programs. We need to include a safe, regulated hemp marketplace, which may be the more practical and scalable starting point, especially when delivered through structured, clinician-guided programs. The organizations that lead here won’t be the ones that move fastest; they’ll be the ones that build the best governance: clear protocols, conservative dosing, outcomes tracking and real clinical oversight. That’s how this category moves from controversy to standard of care.
Brooke Worster Worster, MD, FACP
Disclosures: Worster reports serving as a medical consultant to Ethos Cannabis and EO Care.
<
Leave a Reply